Tango Therapeutics (NASDAQ:TNGX) Insider Sells $798,930.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 27,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.59, for a total transaction of $798,930.00. Following the transaction, the insider owned 115,743 shares in the company, valued at $3,424,835.37. This represents a 18.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Adam Crystal also recently made the following trade(s):

• On Monday, June 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $22.87, for a total transaction of $617,490.00.
• On Friday, May 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.23, for a total value of $573,210.00.
• On Wednesday, April 15th, Adam Crystal sold 38,460 shares of Tango Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $961,500.00.

Tango Therapeutics Stock Performance

TNGX stock opened at $29.46 on Friday. Tango Therapeutics, Inc. has a fifty-two week low of $5.34 and a fifty-two week high of $34.39. The business’s 50 day moving average price is $25.55 and its two-hundred day moving average price is $18.49. The company has a market capitalization of $4.26 billion, a price-to-earnings ratio of -35.49 and a beta of 1.12.

Tango Therapeutics (NASDAQ:TNGX) last announced its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.32). Sell-side analysts forecast that Tango Therapeutics, Inc. will post -1.28 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the company. Stifel Nicolaus raised their price objective on Tango Therapeutics from $24.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Canaccord Genuity Group upped their target price on shares of Tango Therapeutics from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Jefferies Financial Group upgraded shares of Tango Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the stock from $27.00 to $60.00 in a research note on Thursday, June 25th. Raymond James Financial cut shares of Tango Therapeutics to a “hold” rating in a research report on Thursday, June 25th. Finally, B. Riley Financial reissued a “buy” rating on shares of Tango Therapeutics in a research note on Monday, June 8th. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.50.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new stake in Tango Therapeutics in the fourth quarter worth $35,000. Dynamic Technology Lab Private Ltd increased its holdings in shares of Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after acquiring an additional 15,037 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after acquiring an additional 1,640 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Tango Therapeutics by 148,800.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after purchasing an additional 4,464 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd purchased a new position in shares of Tango Therapeutics in the 4th quarter worth about $40,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.